在现实世界大型机构队列中，MOG-IgG对临床定义的MOG-AD的阳性预测价值(S41.003)

摘要目的:在一项大型机构队列研究中，确定血清MOG-IgG对临床定义的MOG-AD的阳性预测价值。

背景:髓磷脂少突胶质细胞糖蛋白相关疾病(MOG-AD)是一种单相或复发性中枢神经系统脱髓鞘疾病，典型表现为视神经炎、横断性脊髓炎和/或adm样综合征。据报道，血清MOG-IgG的阳性预测值(PPV)范围为82-100%，取决于测定和研究设计(沃特斯等人(2019))。

设计/方法:在2017年1月1日至2021年3月25日期间，对马萨诸塞州布里格姆研究中心患者数据注册数据库查询了至少一次血清MOG-IgG检测阳性的患者。所有患者均通过Mayo Clinic MOG-IgG1荧光激活细胞分选试验进行检测。我们回顾了MOG-IgG阳性的病例，以实现由治疗神经科医生和研究作者确定的典型MOG-AD临床特征。

结果:在滴度≥1:20的80例MOG-IgG检测阳性患者中(44F;36米;年龄5-81岁，中位37岁)，67例证实MOG-AD, PPV为83.3%。以≥1:40滴度为临界值，PPV为93.8%。3例MOG阳性病例诊断为典型多发性硬化症(RRMS n= 2,1:20和1:40;项目组合管理系统n = 1;1:10 0)。一位滴度为1:40的RRMS患者的治疗诊断随后被治疗神经科医生修改为MOG-AD。其余无MOG-AD阳性患者的有效诊断包括:偏头痛(n= 2,1:20, 1:100)，包涵体肌炎(n=1;1:100)，自身免疫性脑炎(n=2; 1:20, 1:20), hypoxic ischemic brain injury (n=1; 1:20), IgG4-related disease (n=1, 1:20), idiopathic hypertrophic pachymeningitis (n=1, 1:20) and cases of reported prior monophasic vision loss and sensory changes without supportive objective data (n=2; 1:20, 1:40).

结论:在我们的队列中，滴度≥1:20的MOG-IgG的PPV为83.8%，滴度≥1:40的为93.8%，与先前的报道相当。有或无脱髓鞘特征的阳性病例的存在，强调需要适当的排序，分析滴度值和适当的临床解释。

披露:曼萨诺医生没什么好说的。Salky女士没有什么可透露的。他曾在Horizon Therapeutics的科学咨询或数据安全监测委员会任职，获得500至4,999美元的个人报酬。他曾在Genentech的科学咨询或数据安全监测委员会任职，获得500- 4,999美元的个人报酬。他曾在Biogen的科学咨询或数据安全监测委员会任职，并获得500至4,999美元的个人报酬。Mateen博士曾在TG Therapeutics的科学咨询或数据安全监测委员会任职，并获得了500至4,999美元的个人报酬。Mateen博士曾在EMD Serono的科学咨询或数据安全监测委员会任职，并获得了500- 4,999美元的个人报酬。马丁博士所在的机构得到了基因泰克公司的研究支持。马丁博士所在的研究所得到了NIH的研究支持。马丁博士所在的机构获得了国家多发性硬化症协会的研究支持。 The institution of Dr. Mateen has received research support from Sumaira Foundation. The institution of Dr. Mateen has received research support from EMD Serono. Dr. Mateen has received research support from Biogen. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Galen/Atlantica. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Banner Life Sciences. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. The institution of Dr. Klawiter has received research support from Biogen. The institution of Dr. Klawiter has received research support from Abbvie. The institution of Dr. Klawiter has received research support from Genzyme. The institution of Dr. Klawiter has received research support from Genentech. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Academic CME. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health. Dr. Matiello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VielaBio.